NeuroPace Inc Chief Medical Officer Martha Morrell Sells 17,589 Shares
On February 5, 2024, Chief Medical Officer Martha Morrell sold 17,589 shares of NeuroPace Inc (NASDAQ:NPCE) according to a recent SEC filing. The transaction was executed with the shares priced at $15.09 each, resulting in a total sale amount of $265,423.01.
NeuroPace Inc is a medical device company that designs, develops, and markets implantable devices for the treatment of neurological disorders, including epilepsy. The company's responsive neurostimulation system is designed to detect abnormal electrical activity in the brain and respond by delivering brief and mild electrical stimulation to normalize brain activity before the patient experiences seizures.
Over the past year, Martha Morrell has sold a total of 59,402 shares of NeuroPace Inc and has not made any purchases of the stock. The insider's recent sale contributes to a pattern observed over the last year, where there have been no insider buys and a total of 9 insider sells for the company.
The market capitalization of NeuroPace Inc stands at $409.762 million as of the date of the insider's recent transaction.
Regarding the stock's valuation, NeuroPace Inc's shares were trading at $15.09 on the day of the sale, with a GuruFocus Value (GF Value) of $6.51. This results in a price-to-GF-Value ratio of 2.32, indicating that the stock is significantly overvalued according to GuruFocus metrics.
The GF Value is determined by considering historical trading multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, along with a GuruFocus adjustment factor based on the company's historical returns and growth, and future business performance estimates provided by Morningstar analysts.
The insider trend image above reflects the recent selling activity by insiders at NeuroPace Inc, which aligns with the data indicating a lack of insider purchases over the past year.
The GF Value image provides a visual representation of the stock's current valuation in relation to its intrinsic value estimate, suggesting that the stock is currently trading at a premium to its GF Value.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
